THOMAS MONATH to West Nile Virus Vaccines
This is a "connection" page, showing publications THOMAS MONATH has written about West Nile Virus Vaccines.
Connection Strength
1.391
-
Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses. 2013 Dec 09; 5(12):3048-70.
Score: 0.446
-
Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences. Vaccine. 2007 Nov 19; 25(47):8077-84.
Score: 0.290
-
Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination. J Infect Dis. 2011 Feb 15; 203(4):513-22.
Score: 0.091
-
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010 Jan 08; 28(3):632-49.
Score: 0.083
-
Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE). Vaccine. 2007 Sep 17; 25(37-38):6661-71.
Score: 0.072
-
Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand. Am J Trop Med Hyg. 2006 Nov; 75(5):986-93.
Score: 0.068
-
Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE). Am J Trop Med Hyg. 2006 Oct; 75(4):659-63.
Score: 0.068
-
Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol. 2004 May; 78(9):4761-75.
Score: 0.057
-
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003 Oct 15; 188(8):1213-30.
Score: 0.055
-
Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis. 2002 Dec; 8(12):1392-7.
Score: 0.052
-
Prospects for development of a vaccine against the West Nile virus. Ann N Y Acad Sci. 2001 Dec; 951:1-12.
Score: 0.048
-
A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus. Virology. 2007 Jun 05; 362(2):468-74.
Score: 0.017
-
Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg. 2005 Jan; 72(1):74-81.
Score: 0.015
-
Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am J Trop Med Hyg. 2004 Jan; 70(1):89-97.
Score: 0.014
-
Growth characteristics of the veterinary vaccine candidate ChimeriVax-West Nile (WN) virus in Aedes and Culex mosquitoes. Med Vet Entomol. 2003 Sep; 17(3):235-43.
Score: 0.014